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Th  e association of estrogen receptor (ER) negativity in 
breast cancer with BRCA1 germline mutation carrier 
status is so engrained in the literature that there is a 
tendency to regard all patients with ER-positive tumors 
as sporadic or nonfamilial. In a recent paper published in 
Breast Cancer Research, Tung and colleagues report the 
clinical and histological features of ER-positive breast 
cancers in BRCA1 mutation carriers [1].
Th   e study cohort comprised 172 women with BRCA1-
associated breast cancer, of which 36% were ER-positive. 
Pathological analysis was only possible, however, in 117 
of these patients (68 ER-negative and 49 ER-positive). 
Th  e ER-positive patients were also compared with 138 
matched, population-based, nonfamilial controls. Th  e 
study produced three fundamental conclusions. First, 
there was an association between the ER status of tumors 
in BRCA1 carriers and age of diagnosis – age >50 years 
was a predictor of ER-positive tumors (as was meno-
pausal status, which is associated with age). Second, the 
ER-positive and ER-negative tumors in BRCA1 carriers 
were diﬀ  erent in type, grade, mitotic activity, necrosis 
and type of margins (pushing versus invasive). Finally, the 
ER-positive tumors in BRCA1 carriers were diﬀ  erent to 
sporadic/control ER-positive cancers, showed a trend 
towards higher grade and mitotic activity, and were 
predominantly ductal carcinoma – no special type. Th  is 
last conclusion is the most signiﬁ  cant, suggesting that 
ER-positive,  BRCA1-associated tumors are not simply 
incidental. Although the data are not conclusive, they are 
intriguing.
Th   ere are some inevitable limitations to the study. Th  e 
number of patients analyzed is small, the pathological 
data in parts are incomplete, and the data on ER status 
are a mixture of biochemical and immunohistochemistry 
analyses. Th   e pathologists were blinded to ER status but 
do not appear to have been blinded to BRCA1 status. 
Many of the limitations are unavoidable due to the nature 
of the population studied and the type of analysis 
attempted. However, they do limit the eventual 
conclusions that can be drawn.
Th  ere is a clear and strong association between older 
age (and hence menopausal status) and the development 
of ER-positive breast cancers in BRCA1 mutation carriers. 
Although these data are consistent with those of Vaziri 
and colleagues [2] and Foulkes and colleagues [3], the 
latter study demonstrated that at every age interval, the 
likelihood of developing an ER-negative breast cancer for 
BRCA1  mutation carriers is much greater than in 
controls. Th   ere is also clear evidence in the literature that 
in the general population there is an increase in ER-
positive cancers with increasing age [4,5]. Collectively, 
this would be consistent with the hypothesis that a high 
proportion of ER-positive cancer in BRCA1 mutations 
carriers is incidental. Th   e pathology data from the study, 
however, argue against this. Th   e ER-positive breast cancers 
in BRCA1 mutation carriers are not only diﬀ  erent to the 
ER-negative cancers, they are also diﬀ  erent to sporadic ER-
positive breast cancers in the general population matched 
for age and year of diagnosis. Th  is suggests a biological 
eﬀ  ect, although the exact mechanism remains elusive.
Th   ere are compelling data that estrogen plays a key role 
in the development of BRCA1-dependent breast cancers. 
Premenopausal oophorectomy in BRCA1 mutation 
carriers substantially reduces the risk of subsequent 
carci  noma [6], as does treatment with Tamoxifen [7]. 
Further more,  BRCA1 function is linked to ER expression 
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© 2010 BioMed Central Ltdand knockdown of BRCA1 leads to loss of ER expression 
[8]. It is therefore confusing that some BRCA1 mutation 
carriers develop tumors that are ER-positive. It is not 
clear whether these tumors arise as a result of BRCA1 
haploinsuﬃ   ciency – additional methylation, expression 
and loss of heterozygosity studies are needed to address 
this question. Th   e Consortium of Investigators of 
Modiﬁ  ers  of  BRCA1/2 is currently collecting data to 
stratify BRCA1-associated tumors by ER status in order 
to determine whether polymorphisms that alter the risk 
of ER-positive, but not ER-negative, unselected breast 
cancer also modify risk of ER-positive, but not of ER-
negative,  BRCA1-related breast cancer (GChenevix-
Trench, personal communication).
Th   e authors postulate that ER-positive and ER-negative 
cancers in BRCA1 mutation carriers may arise from 
diﬀ   erent cell populations (early progenitor cells versus 
stem cells). Although it is tempting to speculate on the cell 
of origin, especially as it has recently been suggested that 
BRCA1/basal breast cancers may arise from luminal 
progenitors [9], it is worth noting that we know little about 
cell plasticity in normal development or tumori  genesis. It 
is equally plausible that a combination of age-related 
metabolic changes, locally within the breast and 
systemically, environmental exposures together with the 
predisposition of the cells to genomic instability as a result 
of  BRCA1 DNA repair dysfunction could result in the 
same cell populations producing diﬀ  erent tumor subtypes.
An important unanswered question is whether preven-
tive strategies in BRCA1 mutation carriers will change 
the age distribution and hence the subtypes of cancers 
seen in diagnostic practice, and how this will impact 
management.
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